Prognosis and Treatment of Metastatic Melanoma to the Lungs

Overall Survival and Prognosis

The prognosis of metastatic melanoma to the lungs is poor but significantly better than other metastatic sites, with historical 5-year survival rates of approximately 3-10% for unresected disease, but improving to 27-39% for selected patients who undergo complete surgical resection combined with immunotherapy 1
Stage IV melanoma with distant metastases historically carries a median survival of 6-9 months and long-term survival of less than 10% 1, 2

Ipilimumab (anti-CTLA4 antibody) improved median overall survival to 10-11.2 months in previously treated patients, with 15-20% achieving durable long-term responses 3
Complete surgical resection is the treatment of choice for oligometastatic disease (1-3 lesions) if technically feasible with acceptable morbidity, and should be combined with systemic immunotherapy for optimal outcomes 5
Systemic therapy with checkpoint inhibitors (pembrolizumab, ipilimumab) or targeted therapy (BRAF/MEK inhibitors for appropriate mutations) is indicated for multiple lung metastases or unresectable disease 3
Palliative radiation therapy or stereotactic body radiation therapy (SBRT) can be considered for symptomatic metastases 7, 5

Modern immunotherapies and targeted agents have the potential to achieve long-term remission in a larger proportion of patients than historical data suggest 4
Molecular testing, including BRAF mutation status, is crucial to determine eligibility for targeted therapy that can significantly improve outcomes 4
Surgical resection of multiple metastases is NOT appropriate, and systemic therapy is the preferred approach for widespread disease 6